Bucindolol (hydrochloride)

• UNSPSC Description:

  Bucindolol hydrochloride is a β-adrenergic receptor antagonist with activity in preventing new-onset atrial fibrillation. Bucindolol hydrochloride can reduce heart rate and the occurrence of bradycardia in patients with heart failure and atrial fibrillation[1].

• Target Antigen:

  Adrenergic Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/bucindolol-hydrochloride.html

• Smiles:

  N#CC1=CC=CC=C1OCC(O)CNC(C)(C)CC2=CNC3=C2C=CC=C3.Cl

• Molecular Weight:

  399.91

• References & Citations:

  [1]Liggett SB, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11288-93.|[2]Dose-limiting, adverse event-associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trial

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 2

• CAS Number:

  70369-47-0